These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35747566)

  • 41. Interference of bone marrow CD56
    Theodorakos I; Paterakis G; Papadakis V; Vicha A; Topakas G; Jencova P; Karchilaki E; Taparkou A; Tsagarakis NJ; Polychronopoulou S
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27799. PubMed ID: 31066205
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Expression of CD56 and CD19 in Patients with Newly Diagnosed Multiple Myeloma and Their Relationship with Karyotypes and Prognosis].
    Qiu Q; Zhu P; Wang MJ; Lu XZ; Dong YJ; Sun YH; Wang LH; Zhang Y; Bu DF; Wang WS; Liang ZY; Liu W; Qiu ZX; Ou JP; Cen XN
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):1071-8. PubMed ID: 27531777
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interferon Regulatory Factor 4: An Alternative Marker for Plasma Cells in Daratumumab-Treated Patients With Multiple Myeloma.
    Yang S; Hu Q; Wang X; Qiao S; Qi C; Jin H; Zhong Y
    Int J Lab Hematol; 2024 Sep; ():. PubMed ID: 39267340
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Differentiation stage of myeloma plasma cells: biological and clinical significance.
    Paiva B; Puig N; Cedena MT; de Jong BG; Ruiz Y; Rapado I; Martinez-Lopez J; Cordon L; Alignani D; Delgado JA; van Zelm MC; Van Dongen JJ; Pascual M; Agirre X; Prosper F; Martín-Subero JI; Vidriales MB; Gutierrez NC; Hernandez MT; Oriol A; Echeveste MA; Gonzalez Y; Johnson SK; Epstein J; Barlogie B; Morgan GJ; Orfao A; Blade J; Mateos MV; Lahuerta JJ; San-Miguel JF
    Leukemia; 2017 Feb; 31(2):382-392. PubMed ID: 27479184
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Automated and simplified identification of normal and abnormal plasma cells in Multiple Myeloma by flow cytometry.
    Alaterre E; Raimbault S; Garcia JM; Rème T; Requirand G; Klein B; Moreaux J
    Cytometry B Clin Cytom; 2018 May; 94(3):484-492. PubMed ID: 28865180
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Detection of circulating normal and tumor plasma cells in newly diagnosed patients of multiple myeloma and their associations with clinical and laboratory parameters.
    Gupta L; Suku P; Dash A; Bose P; Sharma P; Mallik N; Sreedharanunni S; Varma N; Jandial A; Malhotra P; Sachdeva MUS
    Curr Probl Cancer; 2024 Feb; 48():101025. PubMed ID: 37951052
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cell surface markers in multiple myeloma.
    Ruiz-Argüelles GJ; San Miguel JF
    Mayo Clin Proc; 1994 Jul; 69(7):684-90. PubMed ID: 8015335
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Old and new immunophenotypic markers in multiple myeloma for discrimination of responding and relapsing patients: The importance of "normal" residual plasma cell analysis.
    Pojero F; Casuccio A; Parrino MF; Cardinale G; Colonna Romano G; Caruso C; Gervasi F
    Cytometry B Clin Cytom; 2015; 88(3):165-82. PubMed ID: 25529228
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Detecting hypodiploidy with endoreduplication and masked hypodiploidy in B-cell acute lymphoblastic leukemia using multicolor flow cytometry.
    Chaturvedi A; Shetty D; Ghogale SG; Deshpande N; Badrinath Y; Chatterjee G; Girase K; Sriram H; Khanka T; Mishra C; Dasgupta N; Gujarathi SA; Rajpal S; Patkar N; Amare-Kadam P; Gujral S; Subramanian PG; Tembhare PR
    Cytometry B Clin Cytom; 2022 May; 102(3):199-208. PubMed ID: 35212133
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunophenotypic Heterogeneity of Polytypic Plasma Cells and the Impact on Myeloma Minimal Residual Disease Detection by Multiparameter Flow Cytometry.
    Schouweiler KE; Karandikar NJ; Holman CJ
    Cytometry B Clin Cytom; 2019 Jul; 96(4):310-318. PubMed ID: 31140731
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma.
    Yousef S; Kovacsovics-Bankowski M; Salama ME; Bhardwaj N; Steinbach M; Langemo A; Kovacsovics T; Marvin J; Binder M; Panse J; Kröger N; Luetkens T; Atanackovic D
    Hum Vaccin Immunother; 2015; 11(7):1606-11. PubMed ID: 26001047
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Analysis of immunophenotype and leukemia associated immunophenotype in 610 patients with acute myeloid leukemia].
    Liu YR; Wang YZ; Chen SS; Chang Y; Fu JY; Li LD; Wang H; Yu H; Jiang B; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2007 Nov; 28(11):731-6. PubMed ID: 18457262
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia.
    Bezdekova R; Jelinek T; Kralova R; Stork M; Polackova P; Vsianska P; Brozova L; Jarkovsky J; Almasi M; Boichuk I; Knechtova Z; Penka M; Pour L; Sevcikova S; Hajek R; Rihova L
    Br J Haematol; 2021 Oct; 195(1):95-107. PubMed ID: 34500493
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Quantification of circulating clonal plasma cells by multiparametric flow cytometry as a prognostic marker in patients with newly diagnosed multiple myeloma.
    Sathya P; Kayal S; Srinivas BH; Hamide A; Kar R
    Int J Lab Hematol; 2023 Dec; 45(6):917-926. PubMed ID: 37632156
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The evaluation of minimal residual disease in multiple myeloma by fluorescent molecular beacons in real time PCR of IgH gene rearrangements and correlation with flow cytometry.
    Kara IO; Duman BB; Afsar CU
    J BUON; 2013; 18(2):442-7. PubMed ID: 23818359
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lymphoplasmacytic lymphoma with IgG or IgA paraprotein: a study of 29 cases including cases that can mimic plasma cell neoplasms.
    Qiu L; Nwogbo OV; Medeiros LJ; Thakral B; Li S; Xu J; You MJ; Wang W; Quesada AE; Ramos CB; McDonnell TJ; Thomas SK; Lin P
    Hum Pathol; 2022 Dec; 130():47-57. PubMed ID: 36244464
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Plasma cell leukemia: a retrospective study of 10 cases.
    Agarwal AD; Brahmbhatt BS; Parikh BP; Shah MJ
    Indian J Cancer; 2014; 51(1):18-9. PubMed ID: 24947090
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Correlation between Expression of CD200 and Regulatory T Cells in Multiple Myeloma and Its Significance in Prognostic Stratification].
    Zhu MX; Wan WL; Li HS; Wang YF; Wang J; Ling HS; Yan XX; Ke XY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Oct; 24(5):1427-1432. PubMed ID: 27784369
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inability of a monoclonal anti-light chain antibody to detect clonal plasma cells in a patient with multiple myeloma by multicolor flow cytometry.
    van Velzen JF; van den Blink D; Bloem AC
    Cytometry B Clin Cytom; 2013; 84(1):30-2. PubMed ID: 23019187
    [TBL] [Abstract][Full Text] [Related]  

  • 60. FxCycle™ Based Ploidy Correlates with Cytogenetic Ploidy in B-Cell Acute Lymphoblastic Leukemia and Is Able to Detect the Aneuploid Minimal Residual Disease Clone.
    Gupta N; Parihar M; Banerjee S; Brahma S; Pawar R; Rath A; Shewale S; Singh M; Sasikumaran Nair Remani A; Krishnan S; Bhatacharyya A; Das A; Kumar J; Bhave S; Radhakrishnan V; Nair R; Chandy M; Mishra D; Arora N
    Cytometry B Clin Cytom; 2019 Sep; 96(5):359-367. PubMed ID: 30715800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.